Evidence map›Paper›PMID 40834066›Full record

ArticleScience advances2025

Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer.

Otto Kauko, Mikko Turunen, Päivi Pihlajamaa, Antti Häkkinen, Rayner M L Queiroz, Mirva Pääkkönen, Sami Ventelä, Massimiliano Gaetani, Susanna L Lundström, Antonio Murgia and 9 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. SMARCD1 and Its Functional Relevance in SWI/SNF and Cancer.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Otto KaukoApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0001-8948-9452
Mikko TurunenApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.
Päivi PihlajamaaApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0001-9725-6907
Antti HäkkinenResearch Program in Systems Oncology, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0002-8081-1588
Rayner M L QueirozDepartment of Biochemistry, University of Cambridge, Cambridge, UK.
Mirva PääkkönenTurku Bioscience, University of Turku and Åbo Akademi University, Turku, Finland.
Sami VenteläTurku Bioscience, University of Turku and Åbo Akademi University, Turku, Finland.
Massimiliano GaetaniChemical Proteomics Core Facility, Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5610-0797
Susanna L LundströmChemical Proteomics Core Facility, Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-2363-4287
Antonio MurgiaDepartment of Biochemistry, University of Cambridge, Cambridge, UK.
Biswajyoti SahuApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0001-6576-5440
Johannes RoutilaDepartment for Otorhinolaryngology-Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.ORCID 0000-0001-5385-7065
Gong-Hong WeiDisease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
Heikki IrjalaDepartment for Otorhinolaryngology-Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.ORCID 0000-0003-3054-4677
Julian L GriffinDepartment of Biochemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0003-1336-7744
Kathryn S LilleyDepartment of Biochemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0594-6543
Teemu KiviojaApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0002-7732-2177
Sampsa HautaniemiResearch Program in Systems Oncology, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0002-7749-2694
Jussi TaipaleApplied Tumor Genomics Program, University of Helsinki, Biomedicum, P.O. Box 63, Haartmaninkatu 8, Helsinki FIN-00014 University of Helsinki, Finland.ORCID 0000-0003-4204-0951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in numerous genes contribute to human cancer, with different oncogenic lesions prevalent in different cancer types. However, the malignant phenotype is simple, characterized by unrestricted cell growth, invasion, and often metastasis. One possible hypothesis explaining this dichotomy is that cancer genes regulate common targets, which then function as master regulators of essential cancer phenotypes. To identify mechanisms that drive the most fundamental feature shared by all tumors-unrestricted cell proliferation-we used a multiomic approach, which identified translation and ribosome biogenesis as common targets of major oncogenic pathways across cancer types. Proteomic analysis of tumors and functional studies of cell cultures established nucleolar and coiled-body phosphoprotein 1 as a key node, whose convergent regulation, both transcriptionally and posttranslationally, is critical for tumor cell proliferation. Our results indicate that lineage-specific oncogenic pathways regulate the same set of targets for growth control, revealing key downstream nodes that could be targeted for therapy or chemoprevention.

Indexed as

NeoplasmsOncogenesCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansProteomicsRibosomes

Identifiers

PMID40834066
PMCPMC13155486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.